Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Chronical Physics of Reporting Person* Chronical Physics of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Chrousos Phaedra</u>					1					curo r	ice [vivi			X	Direc	tor		10% O	wner
(Last) (First) (Middle) C/O VANDA PHARMACEUTICALS INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/14/2021										Office below	er (give title w)		Other (below)	specify	
2200 PENNSYLVANIA AVENUE, SUITE 300E				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)														X Form filed by One Reporting Person					
WASHINGTON DC 20037												Form filed by More than One Reporting Person							
(City)	(Sta	ate) (Z	Zip)																
		Table	I - N	lon-Deriva	tive	Secui	rities	Acc	quir	ed, Di	isposed (of, or	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea				Execution Date,		, T	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Securi Benefi		ities Fo icially (D d Following In		ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							c	Code	v	Amount	(A) or (D)	Price		Transa	nsaction(s) tr. 3 and 4)		. 4)	(1150.4)	
Common Stock 06/14/202			1		S		S ⁽¹⁾		2,075	D	\$19.34	\$19.3408 ⁽²⁾		12,925		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)				cution Date,		Transaction of Code (Instr. Derivativ		ative rities ired sed	Expiration Date (Month/Day/Year)			Amo Seci Und Deri	ount of De urities Se lerlying (In vative urity (Instr. ld 4)		erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	/ [i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisable	Expiration Date	n Title	Amount or Number of Shares						

Explanation of Responses:

- 1. Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.33 to \$19.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Remarks:

/s/ Phaedra Chrousos

06/15/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.